Skip to main content

Table 2 Sample description

From: Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30

 

Total

(N = 51)

Age (in years)

 Mean (SD)

68 (12)

 Median (Min – Max)

71 (26–84)

Gender – Female N (%)

25 (49)

Employment status – N (%)

 Working full-time

7 (14)

 Working part-time

4 (8)

 Retired

22 (43)

 Other*

12 (24)

 Missing

6 (12)

Living situation

 Lives alone

12 (24)

 Lives in a nursing home or assisted living facility

1 (2)

 Lives with a partner, spouse, family or friends

32 (63)

 Missing

6 (12)

Diagnosis – N (%)

 MDS

27 (53)

 CMML

13 (26)

 AML

5 (10)

 Missing**

6 (12)

Number of years since diagnosis)

 Mean (SD)

5.0 (7.4)

 Median (Min – Max)

3 (0–46)

Prognostic risk category (IPSS-R)*** – N(%) in MDS only (Total N = 27)

 Very high (> 6 points)

1 (4)

 High (> 4.5–6 points)

10 (37)

 Intermediate (> 3–4.5 points)

3 (11)

 Don’t know

13 (48)

ECOG status – N (%)

 0 – Fully active

7 (14)

 1 – Restricted in physically strenuous activity but ambulatory

12 (24)

 2 – Ambulatory and capable of all selfcare

4 (9)

 Missing

28 (55)

Stem cell transplant – N (%)

1 (2)

Patients using supportive care therapies****

18 (35)

  1. *Other employment status included student, not employed, retired-not employed, and disabled-not employed
  2. **Missing diagnosis: patient with MDS, CMML, or AML who did not complete the question on the demographic and health information form
  3. ***Prognostic risk category only assessed for patients with HR MDS and CMML (n = 40)
  4. ****Examples of supportive care therapies include transfusions, granulocyte colony stimulating factor, granulocyte macrophage-colony stimulating factor, thrombopoietin, erythropoiesis stimulating agents, etc.